NEW YORK--(BUSINESS WIRE)--Retrophin, LLC, a privately-held New York-based, biotechnology company focused on discovering and developing treatments for rare and life-threatening diseases, today announced that it has entered a sponsored research agreement with St. Jude Children’s Research Hospital. Retrophin will supply funding and a library of replacement therapy compounds for St. Jude to test for potential use in the treatment of PKAN disease.
